Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydrocortisone acetate + lidocaine is a combination pharmaceutical product developed by Reyansh Remedies for rectal administration, typically in the form of a suppository. It combines the anti-inflammatory properties of hydrocortisone acetate, a synthetic corticosteroid that acts as a glucocorticoid receptor agonist, with the local anesthetic effects of lidocaine (also known as lignocaine), which inhibits voltage-gated sodium channels. This dual-action formulation is designed to provide symptomatic relief from pain, itching, and inflammation associated with anorectal conditions such as hemorrhoids, anal fissures, and proctitis. The product is approved and marketed as part of Reyansh Remedies' portfolio of generic medications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrocortisone acetate + lidocaine.